Catalyst Pharmaceuticals Inc

Stock Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Completes NDA Submission to FDA for Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, announced today the completion …

Corey Williams — December 17, 2015, 8:32 AM EDT

Stock Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces Top-Line Results in Phase 1(b) Trial of CPP-115

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced top line …

Corey Williams — December 16, 2015, 9:05 AM EDT

Company Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces Third Quarter 2015 Financial Results and Provides Corporate Update

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results …

Corey Williams — November 9, 2015, 4:44 PM EDT

Stock Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces Poster Presentation at 62nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Barbara …

Corey Williams — October 27, 2015, 9:32 AM EDT

Stock Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces Notice of Allowance of a U.S. Patent Application for the Method of Treating Tourette’s Disorder With GABA-Aminotransferase Inactivators

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the …

Corey Williams — October 13, 2015, 8:23 AM EDT

Company Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces Intent to Develop a Generic Equivalent of Sabril

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the initiation …

Corey Williams — September 9, 2015, 8:10 AM EDT

Company Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Appoints Paul J. Merrigan as Chief Commercial Officer

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment …

Corey Williams — August 17, 2015, 8:34 AM EDT

Stock Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces 2Q:15 Financial Results and Provides Corporate Update

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results …

Corey Williams — August 10, 2015, 4:37 PM EDT

Roth Capital Reiterates Buy on Catalyst Pharmaceutical Partners as Firdapse Filing on Track

In a research report released today, Roth Capital analyst Scott Henry maintained a Buy rating on Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) with a $7.00, which …

Jason Cohen Jason Cohen — July 22, 2015, 11:48 AM EDT

MLV Initiates Buy on Catalyst Pharmaceuticals Inc; Sees 251% Upside For The Stock

In a research report released Wednesday, MLV & Co. analyst Ram Selvaraju initiated coverage on shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) with a Buy …

Jason Cohen Jason Cohen — June 24, 2015, 9:45 AM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts